145.53
前日終値:
$146.00
開ける:
$144.56
24時間の取引高:
1.08M
Relative Volume:
0.94
時価総額:
$14.79B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
22.37
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+2.99%
1か月 パフォーマンス:
+3.62%
6か月 パフォーマンス:
+13.59%
1年 パフォーマンス:
-1.26%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
145.53 | 14.79B | 3.10B | 668.60M | 831.30M | 6.5044 |
|
TAK
Takeda Pharmaceutical Co Adr
|
20.15 | 64.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.97 | 46.62B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.00 | 43.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
77.80 | 32.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
586.48 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-06 | 再開されました | Guggenheim | Buy |
| 2026-06-02 | 再開されました | Goldman | Buy |
| 2026-05-22 | 開始されました | Bernstein | Outperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Healthcare stocks with strong revenue growth and attractive valuations - TradingView
Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope - Finviz
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia - PR Newswire
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Where Will Neurocrine Biosciences Be in 5 Years? - Yahoo Finance
Where Will Neurocrine Biosciences Be in 5 Years? - The Motley Fool
Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Underv - GuruFocus
Neurocrine Biosciences starts Alzheimer's Phase 2 trial - Mugglehead Investment Magazine
Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease - Yahoo Finance
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment - Pluang
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease - TradingView
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PR Newswire
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks? - Simply Wall Street
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PR Newswire
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target - TradingView
RBC keeps USD 187.00 target for Neurocrine Biosciences stock - ad-hoc-news.de
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook - Investing.com
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research
This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research
BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Yahoo Finance
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Arizona Daily Star
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
Neurocrine Biosciences Inc (NBIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DAVID WARREN BOYER | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
4,714 |
736,421 |
0 |
| MATTHEW C ABERNETHY | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
2,311 |
361,024 |
0 |
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
| ERIC BENEVICH | Officer |
Sep 09 '26 |
Proposed Sale |
155.13 |
2,154 |
334,150 |
0 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Sale |
154.61 |
2,154 |
333,030 |
64,408 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Option Exercise |
43.24 |
3,194 |
138,109 |
66,562 |
| Norwalk Leslie V | Director |
Jul 29 '26 |
Option Exercise |
139.43 |
842 |
117,400 |
2,430 |
| Norwalk Leslie V | Director |
Jul 28 '26 |
Sale |
182.01 |
1,250 |
227,508 |
1,588 |
| INGRID DELAET | Officer |
Jul 10 '26 |
Proposed Sale |
180.55 |
4,367 |
788,462 |
0 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Option Exercise |
106.02 |
4,367 |
462,989 |
20,592 |
大文字化:
|
ボリューム (24 時間):